11.15.12
A new clinical study on a reformulated version of HOWARU Restore—part of the Danisco range of probiotics from DuPont Nutrition & Health—indicates a reduction in the risk of antibiotic associated diarrhea in patients undergoing antibiotic therapy.
HOWARU Restore, a unique probiotic formulation incorporated into dietary supplements already sold in 10 countries with great success, has a documented ability to replenish intestinal microbiota during gastrointestinal stresses. DuPont has now introduced an optimized formulation of HOWARU Restore comprised of four key strains from the DuPont Danisco strain portfolio: Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04, Bifidobacterium lactis Bi-07 and Lactobacillus paracasei Lpc-37.
The new formula was tested on 503 patients undergoing antibiotic therapy in a triple-blind, randomized, placebo-controlled study. The HOWARU Restore formulation demonstrated effectiveness in reducing the impact of antibiotic associated diarrhea in patients under antibiotic therapy with: a significant reduction of the number of episodes of antibiotic associated diarrhea; a significant reduction in the duration of diarrhea and the number of liquid stools; and a significant reduction of diarrhea-associated symptoms such as fever, bloating and abdominal pain. For more information: www.dupont.com
HOWARU Restore, a unique probiotic formulation incorporated into dietary supplements already sold in 10 countries with great success, has a documented ability to replenish intestinal microbiota during gastrointestinal stresses. DuPont has now introduced an optimized formulation of HOWARU Restore comprised of four key strains from the DuPont Danisco strain portfolio: Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04, Bifidobacterium lactis Bi-07 and Lactobacillus paracasei Lpc-37.
The new formula was tested on 503 patients undergoing antibiotic therapy in a triple-blind, randomized, placebo-controlled study. The HOWARU Restore formulation demonstrated effectiveness in reducing the impact of antibiotic associated diarrhea in patients under antibiotic therapy with: a significant reduction of the number of episodes of antibiotic associated diarrhea; a significant reduction in the duration of diarrhea and the number of liquid stools; and a significant reduction of diarrhea-associated symptoms such as fever, bloating and abdominal pain. For more information: www.dupont.com